Companies
EdiGene
leading Chinese CRISPR gene editing company; ET-01 (base editing for beta-thalassaemia) in IND-enabling; CRISPR HSC programs under NMPA Fast Track.
- Country
- China
Coverage
| CN | EU | US | |
|---|---|---|---|
| genome-engineering | ✓ | ✓ | ✓ |
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $164M to $180M total funding raised | synbiobeta.com |
| Production site | cGMP manufacturing facility in Guangdong Province launched in 2018 | biospace.com |
| Regulatory approval | NMPA IND approval for ET-01 in January 2021 | thalassaemia.org.cy · biospace.com · businesswire.com · lavfund.com |
| Headcount | approximately 46 employees as of July 2026 | caplight.com · datanyze.com |
| Revenue | Estimated annual revenue between $1.8M and $50M medium confidence | datanyze.com |
Independent sources: biospace.com · businesswire.com · caplight.com · datanyze.com · lavfund.com · synbiobeta.com · thalassaemia.org.cy
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Base editing | genome-engineering | Medium | → |
| Genome editing | genome-engineering | Medium | → |
| Personalized & regenerative medicine | regenerative-personalized | Medium | → |
| Prime editing | genome-engineering | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.